deslanoside
Trade name: cedilanid-d
Deslanoside is a cardiotonic glycoside from the leaves of Digitalis lanata. It is used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). It also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 2 marketing orgs
Timeline
Indications
Approved for
Mechanism of action
- Sodium/potassium-transporting ATPaseINHIBITOR
Sodium/potassium-transporting ATPase inhibitor
Alpha subunit is binding site
- Sodium/potassium-transporting ATPase subunit alpha-1 (ATP1A1) ↗
- Sodium/potassium-transporting ATPase subunit beta-2 (ATP1B2) ↗
- Sodium/potassium-transporting ATPase subunit beta-1 (ATP1B1) ↗
- Sodium/potassium-transporting ATPase subunit alpha-2 (ATP1A2) ↗
- Sodium/potassium-transporting ATPase subunit beta-3 (ATP1B3) ↗
- Sodium/potassium-transporting ATPase subunit alpha-3 (ATP1A3) ↗
- Sodium/potassium-transporting ATPase subunit alpha-4 (ATP1A4) ↗
- Sodium/potassium-transporting ATPase subunit gamma (FXYD2) ↗
- Sodium/potassium-transporting ATPase alpha-1 chain
- Sodium/potassium-transporting ATPase beta-3 chain
- Sodium/potassium-transporting ATPase subunit alpha-2/beta-1
- Sodium/potassium-transporting ATPase subunit alpha-1/beta-1
- Sodium/potassium-transporting ATPase subunit alpha-2/beta-3
- Sodium/potassium-transporting ATPase subunit alpha-2/beta-2
- Sodium/potassium-transporting ATPase beta-1 chain
Approval history
- approved—
Chemistry & pharmacology
SMILES
C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H](C)O3)[C@@H](C)O2)O[C@H]5CC[C@@]6(C)[C@H](CC[C@@H]7[C@@H]6C[C@@H](O)[C@]8(C)[C@H](CC[C@]78O)C9=CC(=O)OC9)C5- Mol. weight
- 943.0791 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaDeslanoside ↗
- NCATSYGY317RK75 ↗
- ChEMBLCHEMBL1614 ↗
Also known as
- (3beta,5beta,12beta)-3-{[beta-d-glucopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide
- (3beta,5beta,12beta)-3-{[beta-d-glucopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide
- 3-[(o-beta-d-glucopyranosyl-(1->4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-3beta,5beta,12beta-card-20(22)-enolide
- 3-[(o-beta-d-glucopyranosyl-(1->4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-3beta,5beta,12beta-card-20(22)-enolide
- cedilanid d
- cedilanid-d
- cedilanid-d
- deacetylanatoside c
- deacetyllanatoside c
- deacetyllanatoside c
- deacetyllanatoside c
- desace
- desacetyl-lanatoside c
- desacetyl-lanatoside c
- desacetyllanatoside c
- desacetyllanatoside c
- desacetyllanatoside c
- deslanatoside c
- deslanoside
- deslanoside
- deslanoside
- deslanoside
- deslanoside
- deslanoside
- deslanoside
- deslanoside
- deslanoside
- deslanoside
- deslanoside c
- deslanosido
- deslanosido
- deslanosidum
- deslanosidum
- glucodigoxin
- glucodigoxin
- purpurea glycoside c